07:04 EDT Phathom Pharmaceuticals (PHAT) sees FY25 revenue $170M-$175M, consensus $170.4M
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals’ EoE Study: A Potential Game-Changer?
- Phathom Pharmaceuticals’ Vonoprazan Pregnancy Study: A Market Game Changer?
- Phathom Pharmaceuticals Publishes Phase 3 Trial Results
- Phathom Pharmaceuticals Appoints New Chief Financial Officer
- Phathom appoints Sanjeev Narula as chief financial, business officer